Eli Lilly’s experimental obesity pill, orforglipron, demonstrated promising results in a late-stage trial, showing an average weight loss of 12% among participants taking the highest dose. The trial involved over 3,000 adults with obesity, and the pill was tested in various doses, with the highest dose resulting in an average loss of approximately 27 pounds. Orforglipron is part of the GLP-1 class of drugs, which includes other weight loss and diabetes treatments such as Ozempic and Wegovy. The trial also indicated potential benefits for type 2 diabetes management, as the pill effectively lowered blood sugar levels. Despite its effectiveness, the pill was associated with gastrointestinal side effects, leading to some participants dropping out of the study. Eli Lilly plans to seek regulatory review for orforglipron by the end of the year.<\/p>\n","protected":false},"excerpt":{"rendered":"
Eli Lilly’s experimental obesity pill, orforglipron, demonstrated promising results in a late-stage trial, showing an average weight loss of 12% among participants taking the highest dose. The trial involved over…<\/p>\n","protected":false},"author":1,"featured_media":951,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1434],"tags":[8647,413,8648,10901,10902],"class_list":["post-10033","post","type-post","status-publish","format-standard","has-post-thumbnail","category-global","tag-eli-lilly","tag-global-startup-news","tag-glp-1-drugs","tag-orforglipron","tag-weight-loss"],"acf":[],"yoast_head":"\n